Table 1

Epidemiologic characteristics of the patients

Chemotherapy cycles in study group (n=182)Chemotherapy cycles in control group (n=483)P value
Age (year), mean±SD54.1±10.552.9±7.10.091
Body height (m), mean±SD58.6±6.957.9±7.10.286
Body weight (kg), mean±SD160.2±4.7160.8±4.50.094
Body mass index (kg/m2), mean±SD22.8±2.422.4±2.80.064
ECOG performance status n (%)0.151
 0105 (57.7%)275 (65.0%)
 154 (29.7%)112 (26.5%)
 223 (12.6%)36 (8.5%)
FIGO stage, n (%)0.274
 I27 (14.8%)48 (11.3%)
 II7 (3.8%)16 (3.8%)
 III122 (67.0%)273 (64.5%)
 IV26 (14.3%)86 (20.3%)
History of radiotherapy, n (%)8 (4.4%)16 (3.8%)0.439
Complications, n (%)
 Hypertension34 (18.7%)97 (22.9%)0.244
 Diabetes7 (3.8%)35 (8.3%)0.049
 Cardiovascular disease0 (0%)6 (1.4%)0.186
 Cerebrovascular disease0 (0%)17 (4.0%)0.006
 DVT16 (8.8%)36 (8.5%)0.910
Chemotherapy cycles, mean±SD0.417
 ≤6141 (77.5%)340 (80.4%)
 >641 (22.5%)83 (19.6%)
Chemotherapy regimen, n (%)0.074
 PC173 (95.1%)384 (90.8%)
 Others9 (4.9%)39 (9.2%)
Bevacizumab, n (%)15 (8.2%)68 (16.1%)0.010
Debulking surgery, n (%)24 (13.2%)55 (13.0%)0.951
  • DVT, Deep Venous Thrombosis; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynaecology and Obstetrics; PC, paclitaxel plus carboplatin.